Lumida
/XOMA
⌘K
Xoma Royalty Corp

Xoma Royalty Corp

XOMA
$40.17USD↑+0.00%+0.00 today

MARKET CAP

710.2M

P/E (TTM)

27.5x

FWD P/E

—

DAY RANGE

$40 – $40

52W RANGE

$22
$45

AI Summary

Stalk
Buy NowHigh

XOMA remains in a Stage 2 advancing uptrend, driven by momentum breakout and Lockout Rally dynamics. Medium-term bias stays bullish on rising EMAs, higher highs and lows, and supportive volume patterns. Short-term bias is bullish under the active Lockout Rally override, permitting immediate continuation participation despite extreme overbought conditions. Execution focuses on the recent breakout zone while monitoring the 9/21 EMA support for potential momentum shifts.

  • ↑2025 revenue surged 83% YoY to $52.1M driven by Vibisimo and Ojemda
  • ↑Added 22 new royalty assets in 2025, enhancing future cash-flow potential
  • ↓Two Phase III clinical failures heighten portfolio volatility
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

XOMA Royalty Corporation (NASDAQ:XOMA) operates as a royalty aggregator in the biotechnology industry, focusing on acquiring rights to biotechnology royalty and milestone assets. Positioned as a growing player in the sector, XOMA strategically hedges risks through diversification and innovative transaction structures. It is emerging as a significant participant in the healthcare space, particularly with its expansion of commercially available programs and active efforts to capture royalties from approved treatments. Given the ongoing growth and strategic initiatives, XOMA is poised to become a notable player in the evolving biotech landscape.

Bull says

  • ↑2025 revenue surged 83% YoY to $52.1M driven by Vibisimo and Ojemda
  • ↑Added 22 new royalty assets in 2025, enhancing future cash-flow potential
  • ↑Generated positive operating cash flow with $83M unrestricted cash on hand
  • ↑Returned $16M via share repurchases, reducing float by over 5%
  • ↑Merger with Ligand offers $39 per share consider­ation, underpinning upside
  • ↑Strong momentum and high earnings yield indicate favorable technical setup

Bear says

  • ↓Two Phase III clinical failures heighten portfolio volatility
  • ↓High dependence on a few core products risks major revenue swings
  • ↓Negative book-to-price ratio suggests potential asset overvaluation
  • ↓Ongoing IP litigation uncertainty may lead to unexpected costs
  • ↓Weak growth outlook and diminished institutional interest may cap upside
  • ↓Small market size and competition increase pressure on royalty margins

Investment themes with XOMA

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR
High Dividend Yield↑ +0.15%

Companies paying above-average dividends

AISP · SMR · NWL

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 07-12-2026neutral

Transcript signals

Bull points

  • During today's call, we will review our 2025 financial results, discuss recent business development activity and portfolio updates and provide commentary on key upcoming catalysts.
  • 2025 was a strong year financially for Zoma Royalty, with full year total gap income and revenue of $52.1 million compared with $28.5 million in 2024, driven by substantial growth in royalties and clinical, regulatory, and business development events.
  • This substantial growth was driven by Vibisimo and Ojemda year-over-year increases, as well as new contribution from Miplypha following its approval for Niemann-Pick disease type C in late 2024.

Bear points

  • $36 million
  • $34.5 million
  • $1.1 million
Read full transcript analysis ›